Evidence map›Paper›PMID 41207941›Full record

ReviewAdvances in experimental medicine and biology2026

Exploring the Protein Landscape of Dormant Mycobacterium tuberculosis Through In Vitro Functional Studies.

Parissa Farnia, Ali Akbar Velayati, Jalaledin Ghanavi, Poopak Farnia

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Parissa FarniaShahid Beheshti University of Medical Sciences, Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Tehran, Iran. farnia@theaasm.org.
Ali Akbar VelayatiShahid Beheshti University of Medical Sciences, Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Tehran, Iran.
Jalaledin GhanaviShahid Beheshti University of Medical Sciences, Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Tehran, Iran.
Poopak FarniaShahid Beheshti University of Medical Sciences, Mycobacteriology Research Centre (MRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The investigation of functional proteins during dormancy in Mycobacterium tuberculosis (Mtb) through in vitro experiments provides crucial insights into the bacterium's survival mechanisms and pathogenicity. Dormancy constitutes a pivotal phase in the Mtb life cycle, enabling the pathogen to persist within hostile host environments, evade immune defenses, and establish latent tuberculosis infections. Although dormancy is often conceptually divided into early, mid, and late stages, these phases frequently overlap, representing a continuum of physiological and molecular adaptations rather than distinct, isolated steps. During early dormancy, which typically occurs within the initial days to weeks following exposure to stressors such as hypoxia and nutrient limitation, Mtb initiates rapid transcriptional and proteomic reprogramming. This reprogramming involves the upregulation of genes associated with stress response, anaerobic metabolism, and cell wall remodeling. These molecular changes drive initial morphological adaptations, including cell wall thickening and a marked reduction in replication rates, signaling the transition from active growth to a nonreplicating persistent state. Mid-dormancy, spanning several weeks to months, is characterized by further metabolic downregulation coupled with enhanced resistance to environmental stresses. Proteins involved in energy conservation, detoxification processes, and maintenance of cellular integrity become increasingly prominent during this phase. Morphologically, Mtb bacilli undergo size reduction, exhibit altered cell division patterns such as budding, and display structural transformations including the folding of rod-shaped cells into ovoid forms. These adaptations collectively support the bacterium's long-term survival under sustained hostile conditions. Late dormancy, which may extend over months or even years, is defined by the stabilization of a metabolically quiescent state accompanied by profound physiological modifications. Morphological hallmarks of this stage include the formation of specialized spore-like cells and filterable nonacid-fast forms. Despite these altered physical characteristics, the cells remain metabolically active, enabling Mtb to withstand prolonged immune pressure and antibiotic exposure. This stage underlies the bacterium's capacity for latent infection and potential reactivation. While the tripartite framework of early, mid, and late dormancy provides a useful conceptual model, the transitions between these stages are naturally gradual and overlapping. Overlapping genetic and phenotypic changes underscore the dynamic and continuous nature of dormancy in Mtb. A comprehensive understanding of the functional proteins and regulatory networks operative throughout these stages is essential not only for elucidating the mechanisms that sustain Mtb during latency but also for identifying novel therapeutic targets. Targeting these pathways holds promise for preventing reactivation and improving the efficacy of tuberculosis treatment.

Indexed as

Bacterial ProteinsLatent TuberculosisMycobacterium tuberculosisGene Expression Regulation, BacterialHumansProteomicsBacterial ProteinsDormancyDormancy survival regulator (DosR)Heat shock protein XMolecular chaperonesMycobacterium tuberculosisSigma factorWhiB-like (Wbl) family

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.